Drug in Pregnancy
... • 2 cases of polyhydramnios reported because of nephrogenic diabetes insipidus in adults taking Lithium the presumed mechanism of polyhydramnios if fetal diabetes insipidus and polyhydramnios may indicate fetal Lithium toxicity. • It is recommended to change medication during pregnancy although repl ...
... • 2 cases of polyhydramnios reported because of nephrogenic diabetes insipidus in adults taking Lithium the presumed mechanism of polyhydramnios if fetal diabetes insipidus and polyhydramnios may indicate fetal Lithium toxicity. • It is recommended to change medication during pregnancy although repl ...
Off-label intravitreal use of the medicinal product Avastin
... A reduction of circulating VEGF concentration has been demonstrated following intravitreal anti-VEGF therapy. Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors, and there is a theoretica ...
... A reduction of circulating VEGF concentration has been demonstrated following intravitreal anti-VEGF therapy. Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors, and there is a theoretica ...
Medication Allergies and Cross-Reactivity
... Previous reaction to a sulfonamide antibiotic was associated with a 2.8 times higher likelihood of having a reaction to the nonantibiotic ...
... Previous reaction to a sulfonamide antibiotic was associated with a 2.8 times higher likelihood of having a reaction to the nonantibiotic ...
LIVALO - Kowa Pharmaceuticals America
... The use of LIVALO is contraindicated in the following conditions: • Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with LIVALO [see Adverse Reactions (6.1)]. • Patients with active liver d ...
... The use of LIVALO is contraindicated in the following conditions: • Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with LIVALO [see Adverse Reactions (6.1)]. • Patients with active liver d ...
PREDICTION OF RENAL IMPAIRMENT INDUCED BY STATIN THERAPY IN CARDIAC OUTPATIENTS
... studies and reports on adverse drug reaction (ADRs) of statins based on doctors’ assessments, few from patient’s self-report. Objectives of this study are to determine the incidences in declining of creatinin clearance (CrCl) and renal ADRs induced by statin. Also, the risk factors of renal function ...
... studies and reports on adverse drug reaction (ADRs) of statins based on doctors’ assessments, few from patient’s self-report. Objectives of this study are to determine the incidences in declining of creatinin clearance (CrCl) and renal ADRs induced by statin. Also, the risk factors of renal function ...
S0735109714017288_mmc1
... statins, defined as inability to tolerate any dose or increase the dose above the smallest tablet strength because of intolerable muscle-related side effects, which resolved or improved significantly upon dose decrease or discontinuation. Major exclusion criteria included New York Heart Association ...
... statins, defined as inability to tolerate any dose or increase the dose above the smallest tablet strength because of intolerable muscle-related side effects, which resolved or improved significantly upon dose decrease or discontinuation. Major exclusion criteria included New York Heart Association ...
New developments in the treatment of acute bacterial skin and skin
... included a terminal half-life of 187.4 hours due to extensive protein binding (93%–98%), a volume of distribution of 0.52 L/kg, and increased penetration of dalbavancin into skin and other peripheral compartments.15 These data suggested that extended interval dosing may be effective, and that a onc ...
... included a terminal half-life of 187.4 hours due to extensive protein binding (93%–98%), a volume of distribution of 0.52 L/kg, and increased penetration of dalbavancin into skin and other peripheral compartments.15 These data suggested that extended interval dosing may be effective, and that a onc ...
otezla - Celgene
... OTEZLA® is contraindicated during pregnancy and should not be used in women attempting to conceive (see CONTRAINDICATIONS). There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OTEZLA® during pregnancy. Information about the registry can be obtained by calling ...
... OTEZLA® is contraindicated during pregnancy and should not be used in women attempting to conceive (see CONTRAINDICATIONS). There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OTEZLA® during pregnancy. Information about the registry can be obtained by calling ...
Antiarrhythmic Drugs
... are reversed. Follow with IV infusion 20–50 mg/kg, rate 1–4 mg/min. Maximum: 200–300 mg/h. Adjustment of dosage • Kidney disease: None. • Liver disease: In acute hepatitis and uncompensated cirrhosis: decrease dose by ...
... are reversed. Follow with IV infusion 20–50 mg/kg, rate 1–4 mg/min. Maximum: 200–300 mg/h. Adjustment of dosage • Kidney disease: None. • Liver disease: In acute hepatitis and uncompensated cirrhosis: decrease dose by ...
QA53_7_Hypersalivationalternatives
... There are no randomised double-blind studies that compare the different therapeutic options available for the management of sialorrhoea (17). An in-depth systematic review of the medical literature investigating the efficacy of anticholinergic drugs to treat drooling in children with multiple disabi ...
... There are no randomised double-blind studies that compare the different therapeutic options available for the management of sialorrhoea (17). An in-depth systematic review of the medical literature investigating the efficacy of anticholinergic drugs to treat drooling in children with multiple disabi ...
BENICAR® Fact Sheet
... of patients treated with BENICAR and at a higher incidence than placebo was dizziness (3 percent vs. 1 percent). The following adverse reactions occurred in placebo-controlled clinical trials at an incidence of more than one (1) percent of patients treated with BENICAR, but also occurred at about th ...
... of patients treated with BENICAR and at a higher incidence than placebo was dizziness (3 percent vs. 1 percent). The following adverse reactions occurred in placebo-controlled clinical trials at an incidence of more than one (1) percent of patients treated with BENICAR, but also occurred at about th ...
Parkinsonism-b
... (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients already taking levodopa (E) Mental disturbances occur more commonly with levo ...
... (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients already taking levodopa (E) Mental disturbances occur more commonly with levo ...
medications used in the management of substance use disorders
... Monitoring, Referrals, and Warnings: Specialty consultation advised. Baseline evaluation include: naloxone challenge test, transaminase levels and urine toxicology. Therapy is most effective when the patient is engaged in addiction-focused counseling with monitored administration. Repeat transaminas ...
... Monitoring, Referrals, and Warnings: Specialty consultation advised. Baseline evaluation include: naloxone challenge test, transaminase levels and urine toxicology. Therapy is most effective when the patient is engaged in addiction-focused counseling with monitored administration. Repeat transaminas ...
International Warnings On Psychiatric And Other Drugs Causing
... to a potentially fatal disorder called Neurolepetic Malignant Syndrome, characterized by muscle rigidity and fever (also associated with agitation, confusion and altered mental status). AstraZeneca's Web site on Seroquel warned potential users about the risks of suicide.38 June 14: Japan’s Health Mi ...
... to a potentially fatal disorder called Neurolepetic Malignant Syndrome, characterized by muscle rigidity and fever (also associated with agitation, confusion and altered mental status). AstraZeneca's Web site on Seroquel warned potential users about the risks of suicide.38 June 14: Japan’s Health Mi ...
Rexogin® 50mg/ml - Alpha
... in headaches, cramps, changes in the HDL and LDL values, and in rare cases, in high blood pressure. When Rexogin® is injected possible liver damage can be estimated as very low; However, in large doses an elevation in the liver values is possible. Since Rexogin® is dissolved in water the injections ...
... in headaches, cramps, changes in the HDL and LDL values, and in rare cases, in high blood pressure. When Rexogin® is injected possible liver damage can be estimated as very low; However, in large doses an elevation in the liver values is possible. Since Rexogin® is dissolved in water the injections ...
TRANSLIPO-3 CREAM
... Carcinogenesis, Mutagenesis, Impairment of Fertility: There was no evidence of carcinogenicity in the study conducted in rats. Studies to assess the mutagenic potential of beclomethasone dipropionate have not been conducted. Impairment of fertility, as evidenced by inhibition of the estrous cycle in ...
... Carcinogenesis, Mutagenesis, Impairment of Fertility: There was no evidence of carcinogenicity in the study conducted in rats. Studies to assess the mutagenic potential of beclomethasone dipropionate have not been conducted. Impairment of fertility, as evidenced by inhibition of the estrous cycle in ...
ATROVENT® Metered Aerosol (CFC-free) - Boehringer
... CFC-containing metered aerosols. The safety and efficacy of ATROVENT CFC-free metered aerosol, in chronic obstructive pulmonary disease (COPD) and asthma, was established from the results of one 12-month and two 12-week safety and efficacy trials conducted in COPD, a 12-week study in asthmatic adul ...
... CFC-containing metered aerosols. The safety and efficacy of ATROVENT CFC-free metered aerosol, in chronic obstructive pulmonary disease (COPD) and asthma, was established from the results of one 12-month and two 12-week safety and efficacy trials conducted in COPD, a 12-week study in asthmatic adul ...
Harvey M. Richey DO, FCCP Interim Regional Chairman Department of Medicine
... When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice. Patients with cavitation on initial chest radiograph an ...
... When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice. Patients with cavitation on initial chest radiograph an ...
Adverse Effects were not the Main Causes for Rotigotine Patch
... [13]. However, the concommitant safety issues may compromise its wide application [14]. Previous studies showed that the most common adverse events in PD patients who received rotigotine patch were application site reactions, the frequency of which can reach 44-46% [13,15]. Other side effects of rot ...
... [13]. However, the concommitant safety issues may compromise its wide application [14]. Previous studies showed that the most common adverse events in PD patients who received rotigotine patch were application site reactions, the frequency of which can reach 44-46% [13,15]. Other side effects of rot ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These
... ----------------------- USE IN SPECIFIC POPULATIONS ----------------------Lactation: Do not breastfeed. (8.2) See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. ...
... ----------------------- USE IN SPECIFIC POPULATIONS ----------------------Lactation: Do not breastfeed. (8.2) See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. ...
Camptosar - DavisPlus
... sites for 10 min. Assess for signs of infection during neutropenia. Anemia may occur. Monitor for increased fatigue, dyspnea, and orthostatic hypotension. Monitor closely for the development of diarrhea. Two types may occur. The early type occurs within 24 hr of administration and may be preceded by ...
... sites for 10 min. Assess for signs of infection during neutropenia. Anemia may occur. Monitor for increased fatigue, dyspnea, and orthostatic hypotension. Monitor closely for the development of diarrhea. Two types may occur. The early type occurs within 24 hr of administration and may be preceded by ...
PACKAGE INSERT TEMPLATE FOR ACETYLSALICYLIC ACID
... active site of the enzyme, and most of its pharmacological effects are due to inhibition of the formation of cyclo-oxygenase products including thromboxanes, prostaglandins and prostacyclin. Acetylsalicylic acid has an active metabolite (salicylate) which, in addition to possessing some antiinflamma ...
... active site of the enzyme, and most of its pharmacological effects are due to inhibition of the formation of cyclo-oxygenase products including thromboxanes, prostaglandins and prostacyclin. Acetylsalicylic acid has an active metabolite (salicylate) which, in addition to possessing some antiinflamma ...
FLUNIXAMINE | nOnStEROIDAl AntI
... with the terminal elimination phase (Vß). This discrepancy to drug-associated adverse effects varies with the individual appears to be attributable to extended drug elimination patient. Patients at greatest risk for renal toxicity are those from a deep compartment.8 The terminal half-life has that a ...
... with the terminal elimination phase (Vß). This discrepancy to drug-associated adverse effects varies with the individual appears to be attributable to extended drug elimination patient. Patients at greatest risk for renal toxicity are those from a deep compartment.8 The terminal half-life has that a ...
Oral Health Care for People With HIV Infection PDF
... serious and potentially fatal side effect. Clinical features include fever, skin rash, fatigue, malaise, gastrointestinal (GI) symptoms, arthralgia, cough and/or dyspnea. ...
... serious and potentially fatal side effect. Clinical features include fever, skin rash, fatigue, malaise, gastrointestinal (GI) symptoms, arthralgia, cough and/or dyspnea. ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.